Related Experiment Videos
Further virological and clinical investigations on the attenuated E5"14" virus from the tick-borne excephalitis
Abstract:
A total of 22 persons, given a single intramuscular dose of 3.1 times 10(6) newborn mouse ic LD50/ml of the E5"14" virus (stored for 26 months at 4 degrees C in lyophilized state), were subjected to rigorous clinical, clinical-laboratory and virological investigations. Clinical observations and laboratory tests (blood and cerebrospinal fluid cytology and biochemistry) revealed no ill-effects or deviations attributable to the immunization procedure. After administration of the immunizing dose, no viraemia was detected and specific seroconversions from negativity to positivity were found after 9 weeks in 73-82% of the subjects, using different tick-borne encephalitis (western subtype) viruses in the virus neutralization experiments. The results obtained seem to give increased confidence in the further use of this attenuated virus clone with strictly defined characteristics.
Insights
This study found that an attenuated E5"14" virus vaccine clone, administered intramuscularly, showed no adverse effects in 22 individuals. The tick-borne encephalitis vaccine demonstrated significant seroconversion rates after nine weeks.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Tick-borne encephalitis (TBE) poses a significant public health concern.
- Development of safe and effective TBE vaccines is crucial for disease prevention.
- Attenuated virus vaccine candidates require rigorous safety and immunogenicity evaluation.
Purpose of the Study:
- To assess the safety and immunogenicity of an attenuated E5"14" virus clone for potential TBE vaccination.
- To evaluate clinical, laboratory, and virological parameters following immunization.
Main Methods:
- 22 individuals received a single intramuscular dose of the E5"14" virus.
- Comprehensive clinical observations and laboratory tests (blood, CSF cytology/biochemistry) were performed.
- Virological investigations included assessment for viraemia and virus neutralization experiments for seroconversion.
Main Results:
- No adverse clinical or laboratory effects were observed post-immunization.
- No viraemia was detected after vaccine administration.
- Seroconversion rates ranged from 73-82% after 9 weeks, indicating an immune response.
Conclusions:
- The attenuated E5"14" virus clone demonstrated a favorable safety profile.
- The vaccine candidate induced a significant serological response in the majority of subjects.
- Results support the continued use of this well-defined, attenuated virus clone.